Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 25
Filtrer
1.
Am J Respir Crit Care Med ; 163(7): 1683-92, 2001 Jun.
Article de Anglais | MEDLINE | ID: mdl-11401894

RÉSUMÉ

Here we report the effects of gentamicin treatment on cystic fibrosis transmembrane regulator (CFTR) production and function in CF airway cells and patients with CF with premature stop mutations. Using immunocytochemical and functional [6-methoxy-N- (3-sulfopropyl) quinolinium (SPQ)-based] techniques, ex vivo exposure of airway cells from stop mutation CF patients led to the identification of surface-localized CFTR in a dose-dependent fashion. Next, five patients with CF with stop mutations and five CF control subjects were treated with parenteral gentamicin for 1 wk, and underwent repeated in vivo measures of CFTR function (nasal potential difference [PD] measurements and sweat chloride [Cl(-)] testing). During the treatment period, the number of nasal PD readings in the direction of Cl(-) secretion was increased approximately 3-fold in the stop mutation patient group compared with controls (p < 0.001), and four of five stop mutation patients with CF had at least one reading during gentamicin treatment with a Cl(-) secretory response of more than -5 mV (hyperpolarized). A response of this magnitude was not seen in any of the CF control subjects (p < 0.05). In an independent series of experiments designed to test the ability of repeat nasal PDs to detect wild-type CFTR function, evidence of Cl(-) secretion was seen in 88% of control (non-CF) nasal PDs, and 71% were more than -5 mV hyperpolarized. Together, these results suggest that gentamicin treatment can suppress premature stop mutations in airway cells from patients with CF, and produce small increases in CFTR Cl(-) conductance (as measured by the nasal PD) in vivo.


Sujet(s)
Codon non-sens/effets des médicaments et des substances chimiques , Protéine CFTR/génétique , Mucoviscidose/génétique , Gentamicine/pharmacologie , Adolescent , Adulte , Cellules cultivées , Chlorures/métabolisme , Mucoviscidose/métabolisme , Mucoviscidose/physiopathologie , Protéine CFTR/biosynthèse , Protéine CFTR/physiologie , Femelle , Gentamicine/administration et posologie , Humains , Perfusions veineuses , Mâle , Potentiels de membrane , Microscopie de fluorescence , Muqueuse nasale/métabolisme , Muqueuse nasale/physiopathologie
2.
Hum Gene Ther ; 12(7): 751-61, 2001 May 01.
Article de Anglais | MEDLINE | ID: mdl-11339892

RÉSUMÉ

Immunologic reactivity to lipid-DNA conjugates has traditionally been viewed as less of an issue than with viral vectors. We performed a dose escalation safety trial of aerosolized cystic fibrosis transmembrane conductance regulator (CFTR) cDNA to the lower airways of eight adult cystic fibrosis patients, and monitored expression by RT-PCR. The cDNA was complexed to a cationic lipid amphiphile (GL-67) consisting of a cholesterol anchor linked to a spermine head group. CFTR transgene was detected in three patients at 2-7 days after gene administration. Four of the eight patients developed a pronounced clinical syndrome of fever (maximum of 103.3EF), myalgias, and arthralgia beginning within 6 hr of gene administration. Serum IL-6 but not levels of IL-8, IL-1, TNF-alpha, or IFN-gamma became elevated within 1-3 hr of gene administration. No antibodies to the cationic liposome or plasmid DNA were detected. We found that plasmid DNA by itself elicited minimal proliferation of peripheral blood mononuclear cells taken from study patients, but led to brisk immune cell proliferation when complexed to a cationic lipid. Lipid and DNA were synergistic in causing this response. Cellular proliferation was also seen with eukaryotic DNA, suggesting that at least part of the immunologic response to lipid-DNA conjugates is independent of unmethylated (E. coli-derived) CpG sequences that have previously been associated with innate inflammatory changes in the lung.


Sujet(s)
Protéine CFTR/génétique , Mucoviscidose/génétique , Mucoviscidose/thérapie , ADN/effets indésirables , Thérapie génétique/effets indésirables , Lipides/effets indésirables , Administration par inhalation , Adolescent , Adulte , Animaux , Cations/administration et posologie , Cations/effets indésirables , Cations/immunologie , Division cellulaire/effets des médicaments et des substances chimiques , Ilots CpG/génétique , Protéine CFTR/métabolisme , Protéine CFTR/usage thérapeutique , ADN/administration et posologie , ADN/immunologie , ADN/usage thérapeutique , Femelle , Humains , Inflammation/induit chimiquement , Inflammation/immunologie , Inflammation/anatomopathologie , Lipides/administration et posologie , Lipides/immunologie , Activation des lymphocytes/effets des médicaments et des substances chimiques , Mâle , Monocytes/immunologie , Réaction de polymérisation en chaîne , ARN messager/analyse , ARN messager/génétique , Appareil respiratoire/effets des médicaments et des substances chimiques , Appareil respiratoire/immunologie , Appareil respiratoire/anatomopathologie , Syndrome , Facteurs temps , Transgènes/génétique
4.
Pediatr Pulmonol ; 28(2): 94-100, 1999 Aug.
Article de Anglais | MEDLINE | ID: mdl-10423308

RÉSUMÉ

Chronic pulmonary aspiration (CPA) causes significant morbidity, but is underdiagnosed because of difficulties in establishing a diagnosis. The lipid-laden macrophage index (LLMI) is said to differentiate between those with and without CPA. Records of 113 patients were reviewed to determine specificity and sensitivity of the LLMI for CPA. Diagnostic accuracy was inferred from treatment outcome. Mean LLMI for aspirators was 104 +/- 62 (range, 20-233), and for nonaspirators, 44 +/- 39 (range, 0-170) (P < 0.05). Sensitivity and specificity were 0.69 and 0.79, respectively. While the LLMI provides clinically helpful information, it does not stand alone as the gold standard for the diagnosis of CPA. Failure to thrive and neurological impairment correlated with CPA, using Fisher's exact test. CPA was not diagnosed in any patient with normal growth, normal neurological development, and an LLMI <86. No other clinical observation (cough, wheeze, vomiting, difficulty feeding, choking with feeding, recurrent pneumonia, bronchopulmonary dysplasia, chronic chest X-ray changes, endotracheal tube, tracheostomy tube, nasogastric feeding tube, or transpyloric feeding tube) or diagnostic study (upper gastrointestinal series, gastroesophageal scintigraphy, modified barium swallow, or pH probe) correlated with the diagnosis of CPA.


Sujet(s)
Lipides/analyse , Macrophages alvéolaires/composition chimique , Pneumopathie de déglutition/diagnostic , Adolescent , Liquide de lavage bronchoalvéolaire/cytologie , Enfant , Enfant d'âge préscolaire , Maladie chronique , Cytodiagnostic , Diagnostic différentiel , Humains , Nourrisson , Nouveau-né , Sensibilité et spécificité
7.
Pediatr Res ; 23(1): 81-5, 1988 Jan.
Article de Anglais | MEDLINE | ID: mdl-3277151

RÉSUMÉ

Group B beta-hemolytic Streptotocci cause pulmonary hypertension when injected into animals and may precipitate the persistent pulmonary hypertension syndrome in infected human neonates. We used chronically instrumented piglets to study the effects of repeated injections of heat-killed group B Streptococcus (GBS) type III. Daily exposure to GBS was associated with a 2-fold or greater potentiation of pulmonary and systemic hypertensive responses after 1 wk. Throughout experimentation, pulmonary pressure changes were more marked than systemic changes. After establishing a dose-response relationship, we chose a control dose that produced intermediate hypertensive responses. We then evaluated the effects of antibody and various drugs on the hypertensive responses. Preincubation of organisms with rabbit antiserum containing type-specific antibody enhanced the responses. Beta endorphin blockade with naloxone had little or no effect; leukotriene synthesis inhibition also did not affect responses. Both indomethacin, a cyclooxygenase inhibitor, and dazmegrel, a specific thromboxane synthesis inhibitor, blocked the hypertensive responses to GBS. It appears that repeated doses of GBS potentiate the hypertensive responses, a process that we hypothesize may be mediated by development of type-specific antibody as type-specific antibody levels rose during potentiation. It is likely that thromboxane A2 is the effector of the pulmonary and systemic hypertensive responses to GBS injection, because thromboxane inhibition by dazmegrel was as effective as indomethacin in blocking these effects. Thromboxane synthesis blockade may prove useful in management of hemodynamic disturbances accompanying severe bacterial infections in humans.


Sujet(s)
Hémodynamique , Hypertension pulmonaire/physiopathologie , Infections à streptocoques/physiopathologie , Animaux , Anticorps antibactériens/biosynthèse , Femelle , Hypertension pulmonaire/traitement médicamenteux , Hypertension pulmonaire/étiologie , Imidazoles/usage thérapeutique , Indométacine/usage thérapeutique , Naloxone/usage thérapeutique , Infections à streptocoques/complications , Streptococcus agalactiae/immunologie , Suidae
8.
Crit Care Med ; 15(7): 644-7, 1987 Jul.
Article de Anglais | MEDLINE | ID: mdl-3297489

RÉSUMÉ

Group B Streptococcus (GBS) sepsis in humans may cause the persistent pulmonary hypertension syndrome. Infusions of GBS in animals elevate pulmonary artery pressure (PAP) and resistance and are associated with elevated thromboxane levels. We investigated the hemodynamic effects of the specific thromboxane synthesis inhibitor, dazmegrel, in a piglet model of GBS-induced pulmonary hypertension. PAP rose from 22 +/- 6 to 42 +/- 11 (SD) mm Hg during infusion of heat-killed GBS; pulmonary vascular resistance increased from 1440 +/- 400 to 4000 +/- 1040 dyne X sec/cm5. No significant changes in cardiac output, mean arterial pressure, or left atrial pressure were noted. Treatment with 1 mg/kg of dazmegrel resulted in a rapid return of PAP and resistance to control values. No other hemodynamic effects of either bacteria or drug were observed despite continued infusion of GBS.


Sujet(s)
Hypertension pulmonaire/prévention et contrôle , Imidazoles/usage thérapeutique , Sepsie/complications , Infections à streptocoques/complications , Thromboxane-A synthase/antagonistes et inhibiteurs , Animaux , Pression sanguine , Débit cardiaque , Femelle , Hypertension pulmonaire/étiologie , Artère pulmonaire/physiopathologie , Streptococcus agalactiae , Suidae
9.
J Pediatr ; 110(1): 97-101, 1987 Jan.
Article de Anglais | MEDLINE | ID: mdl-3794894

RÉSUMÉ

Neonatal herpes simplex virus (HSV) infection is usually acquired at birth, although a few infants have had findings suggestive of intrauterine infection. We describe 13 babies who had clinical manifestations of intrauterine HSV infection, including skin lesions and scars at birth (12), chorioretinitis (eight), microcephaly (seven), hydranencephaly (five), and microphthalmia (two). All infants had combinations of these defects. Infection was proved by viral isolation in each case; all isolates were HSV-2. Two infants died during the first week of life; 10 of the surviving infants had severe neurologic sequelae, and one infant was blind. Four mothers experienced an apparent primary genital HSV infection, and one had recurrent infection, at varying times during gestation. The remaining women denied a history of symptoms of genital HSV infection. These findings indicate that intrauterine HSV infection can occur as a consequence of either primary or recurrent maternal infection and has severe consequences for the fetus.


Sujet(s)
Malformations multiples/étiologie , Maladies foetales/étiologie , Herpès/transmission , Complications infectieuses de la grossesse , Adolescent , Adulte , Système nerveux central/malformations , Choriorétinite/étiologie , Méthode en double aveugle , Femelle , Maladies foetales/traitement médicamenteux , Herpès/traitement médicamenteux , Humains , Nouveau-né , Mâle , Microphtalmie/étiologie , Grossesse , Pronostic , Récidive , Malformations cutanées
10.
Dev Pharmacol Ther ; 9(4): 260-5, 1986.
Article de Anglais | MEDLINE | ID: mdl-3530674

RÉSUMÉ

Infusions of group B streptococci cause pulmonary hypertension in several neonatal animal models. A continuous infusion of prostaglandin D2 reduced the magnitude of this pulmonary hypertensive response; indomethacin completely blocked the response. Prostaglandin D2 or cyclooxygenase inhibitors may be important therapeutic agents for infants with group B streptococcal sepsis who manifest pulmonary hypertension.


Sujet(s)
Hémodynamique/effets des médicaments et des substances chimiques , Hypertension pulmonaire/physiopathologie , Prostaglandines D/pharmacologie , Circulation pulmonaire/effets des médicaments et des substances chimiques , Infections à streptocoques/physiopathologie , Animaux , Animaux nouveau-nés , Pression sanguine/effets des médicaments et des substances chimiques , Indométacine/pharmacologie , Prostaglandine D2 , Ovis , Streptococcus agalactiae , Résistance vasculaire/effets des médicaments et des substances chimiques
11.
Pediatr Res ; 19(12): 1268-71, 1985 Dec.
Article de Anglais | MEDLINE | ID: mdl-4080444

RÉSUMÉ

Hyperventilation (respiratory alkalosis) is an important treatment for persistent pulmonary hypertension in neonates. The precise way that hyperventilation attenuates hypoxic pulmonary vasoconstriction is unclear. We studied the effect of alkalosis on hypoxia-induced pulmonary vasoconstriction in 13 acutely instrumented, pentobarbital anesthetized, neonatal lambs. We specifically examined the relative effects of a metabolic alkalosis versus a respiratory alkalosis on hypoxic pulmonary vasoconstriction and compared these results to the control response to hypoxia without alkalosis. Hypoxic pulmonary vasoconstriction was significantly milder whenever the animal was alkalotic, regardless of whether the alkalosis was respiratory of metabolic. Thus, the elevated pHa rather than decreased PaCO2 during hyperventilation appears to be the major factor in moderating the response of the pulmonary vessels to acute hypoxia in this neonatal lamb model.


Sujet(s)
Alcalose respiratoire/physiopathologie , Hypoxie/physiopathologie , Circulation pulmonaire , Vasoconstriction , Animaux , Animaux nouveau-nés , Pression sanguine , Humains , Hypertension pulmonaire/congénital , Hypertension pulmonaire/thérapie , Nouveau-né , Ovis , Résistance vasculaire
13.
Pediatr Pharmacol (New York) ; 5(1): 23-30, 1985.
Article de Anglais | MEDLINE | ID: mdl-3991251

RÉSUMÉ

We studied the effects of nifedipine, a calcium-channel blocker, in two acutely instrumented groups of newborn lambs during normoxic and hypoxic conditions. Nifedipine at 10 or more micrograms/kg reduced systemic, but not pulmonary artery pressure and resistance in normoxic lambs. When acute hypoxia was produced in these animals, 50 or more micrograms/kg reduced, but did not prevent, the expected rise in pulmonary pressure and resistance. When infused into already hypoxic lambs, nifedipine in doses of 50 micrograms/kg or more reduced both systemic and pulmonary pressures and resistances equally. Thus, nifedipine is a nonspecific vasodilator in newborn lambs.


Sujet(s)
Hémodynamique/effets des médicaments et des substances chimiques , Hypoxie/médecine vétérinaire , Nifédipine/pharmacologie , Analyse de variance , Animaux , Animaux nouveau-nés , Gazométrie sanguine , Pression sanguine/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Hypertension pulmonaire/traitement médicamenteux , Hypoxie/traitement médicamenteux , Perfusions parentérales , Nifédipine/usage thérapeutique , Pression artérielle pulmonaire d'occlusion/effets des médicaments et des substances chimiques , Ovis , Maladies des ovins
14.
Clin Perinatol ; 11(3): 551-64, 1984 Oct.
Article de Anglais | MEDLINE | ID: mdl-6386269

RÉSUMÉ

This article describes the anatomy and physiology of the fetal, transitional, and neonatal circulations and then reviews our current state of knowledge about the many factors that work in concert to govern pulmonary vascular resistance.


Sujet(s)
Foetus/physiologie , Nouveau-né , Circulation pulmonaire , Résistance vasculaire , Acétylcholine/physiologie , Équilibre acido-basique , Angiotensines/physiologie , Animaux , Animaux nouveau-nés , Système nerveux autonome/physiologie , Viscosité sanguine , Bradykinine/physiologie , Catécholamines/physiologie , Bovins , Femelle , Histamine/physiologie , Humains , Hypoxie/physiopathologie , Oxygène/sang , Grossesse , Prostaglandines/physiologie , Sérotonine/physiologie , Ovis , Vasoconstriction
15.
Clin Perinatol ; 11(3): 565-79, 1984 Oct.
Article de Anglais | MEDLINE | ID: mdl-6386270
16.
Article de Anglais | MEDLINE | ID: mdl-6874481

RÉSUMÉ

Intrapulmonary injections of prostaglandin D2 (PGD2) reduce pulmonary arterial pressure and resistance in fetal and hypoxic neonatal lambs without affecting systemic arterial pressure. This apparently specific pulmonary effect of PGD2 could be explained by inactivation of the agent during passage through the pulmonary capillary bed. We therefore studied the effects of both pulmonary and systemic infusions of PGD2 on the acute vascular response to a 1-min episode of hypoxia in newborn lambs. Since PGD2 has been reported to be a pulmonary vasoconstrictor in normoxic lambs, we also evaluated its effects during normoxemia. Pulmonary vascular pressures were not affected by either 1- or 10-micrograms . kg-1 . min-1 infusions into the left atrium or inferior vena cava during normoxia. Infusion of 1 microgram . kg-1 . min-1 PGD2 into the inferior vena cava decreased pulmonary vascular resistance and increased systemic arterial pressure. These two parameters were unchanged with the other three infusion regimens. Mean pulmonary vascular resistance rose 83% with hypoxia and no PGD2. PGD2 prevented any change in pulmonary vascular resistance with hypoxia, while systemic arterial pressure increased (1-microgram . kg-1 . min-1 doses) or was unchanged. Thus PGD2 specifically prevents hypoxic pulmonary vasoconstriction while maintaining systemic pressures, regardless of infusion site. PGD2 may be indicated in treatment of persistent pulmonary hypertension of the newborn and other pulmonary hypertensive disorders.


Sujet(s)
Animaux nouveau-nés/physiologie , Hypoxie/physiopathologie , Prostaglandines D/pharmacologie , Prostaglandines/pharmacologie , Circulation pulmonaire , Ovis/physiologie , Vasoconstriction/effets des médicaments et des substances chimiques , Animaux , Prostaglandines D/administration et posologie , Résistance vasculaire/effets des médicaments et des substances chimiques
18.
J Pediatr ; 100(2): 284-90, 1982 Feb.
Article de Anglais | MEDLINE | ID: mdl-6276524

RÉSUMÉ

Meconium aspiration syndrome often produces respiratory failure in the neonate. We utilized the multiple inert gas elimination technique to study the effects on respiratory and inert gas exchange of the application of positive end expiratory pressure or continuous infusion of tolazoline HCl. The application of PEEP, with the optimal level of PEEP defined for each animal, produced a decrease in AaDO2 and pulmonary shunt, without an increase in blood flow to low VA/Q areas, or an increase in dead space. Tolazoline infusion, at 2 mg/kg/hour, had no apparent effect on AaDO2 or shunt, or magnitude of low VA/Q regions. Tolazoline therapy was associated with an increase in heart rate and a decrease in systemic blood pressure. We conclude that immediate postaspiration application of PEEP, but not of tolazoline, will diminish pulmonary shunt without creating low VA/Q areas, and therefore will improve gas exchange in MAS.


Sujet(s)
Animaux nouveau-nés/physiologie , Méconium/effets des médicaments et des substances chimiques , Gaz rares/métabolisme , Ventilation à pression positive/méthodes , Respiration/effets des médicaments et des substances chimiques , Tolazoline/pharmacologie , Animaux , Pression sanguine/effets des médicaments et des substances chimiques , Rythme cardiaque/effets des médicaments et des substances chimiques , Consommation d'oxygène/effets des médicaments et des substances chimiques , Alvéoles pulmonaires/effets des médicaments et des substances chimiques , Circulation pulmonaire/effets des médicaments et des substances chimiques , Ovis , Rapport ventilation-perfusion/effets des médicaments et des substances chimiques
19.
Pediatrics ; 67(6): 790-5, 1981 Jun.
Article de Anglais | MEDLINE | ID: mdl-7232043

RÉSUMÉ

Adult respiratory distress syndrome, commonly seen in adults, is not well recognized in children. A retrospective chart review was carried out to determine the relative incidence, predisposing conditions, clinical course, and outcome of children with adult respiratory distress syndrome. fifteen patients were identified. The most common predisposing conditions were near-drowning and near-strangulation with a noticeable absence of major trauma. Mortality was 60%. Death was most often secondary to central nervous system complications. Air leak was the most common complication of treatment. Two of six survivors suffered major neurologic handicaps. Long-term pulmonary sequelae were minimal.


Sujet(s)
Unités de soins intensifs , Évaluation des résultats et des processus en soins de santé , Pédiatrie , /étiologie , Adolescent , Obstruction des voies aériennes/complications , Obstruction des voies aériennes/imagerie diagnostique , Maladies du système nerveux central/étiologie , Enfant , Enfant d'âge préscolaire , Noyade/complications , Femelle , Humains , Nourrisson , Mâle , Radiographie , Ventilation artificielle , /mortalité , /thérapie , Études rétrospectives
20.
Article de Anglais | MEDLINE | ID: mdl-6785264

RÉSUMÉ

The feasibility and efficiency of ventilation by high-frequency oscillation (HFO) were examined in animals with diffuse hemorrhagic lung disease. Twenty-four hours after injection with 0.12 ml/kg oleic acid, 11 spontaneously breathing rabbits had a mean (+/- SD) arterial O2 partial pressure (PaO2) of 65 +/- 16 Torr and arterial CO2 partial pressure (PaCO2) of 38 +/- 7 Torr [inspired fractional O2 concentration (FIO2) of 0.21]. Following paralysis animals were ventilated using a high-frequency oscillator for periods of 20 min followed by three successive hyperinflations to prevent atelectasis. Maintaining a constant mean airway pressure (MAP) of 6 cmH2O and fresh gas flow (FGF) of 2 1/min (FIO2 = 0.21), all combinations of frequency (5, 10, 20, and 30 Hz) and stroke volume (Vs) 2.6, 5.0, and 8.9 ml) were tested. At each frequency, an increase in Vs tended to lower mean PaCO2. At each Vs, CO2 elimination appeared maximal at 20 Hz, an effect attributable to decreasing effective Vs with increasing frequency. With constant Vs, MAP, and frequency, increasing FGF from 1 to 2 or 61/min decreased mean PaCO2 (P less than 0.05). With constant Vs, frequency, and FGF, increases in MAP from 2 to 10 cmH2O increased mean PaO2 (P less than 0.05). HFO, coupled with periodic hyperinflation, supports satisfactory gas exchange in rabbits with oleic acid lung injury. The efficiency of gas exchange is improved by independent increases in Vs, FGF, MAP, or frequency.


Sujet(s)
Maladies pulmonaires/induit chimiquement , Acides oléiques/toxicité , Respiration/effets des médicaments et des substances chimiques , Animaux , Dioxyde de carbone/sang , Hémodynamique/effets des médicaments et des substances chimiques , Hémorragie/induit chimiquement , Oxygène/sang , Lapins
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...